Otros idiomas Cardiol Therapeutics Inc.

Acciones

CRDL

CA14161Y2006

Mercado cerrado - Toronto S.E. Otros sitios de cotización 22:00:00 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3,57 ^CAD	+1,13 %		+10,87 %	+224,55 %

24/05	CARDIOL THERAPEUTICS INC. : Recibe una recomendación de compra del Canaccord Genuity	ZM
14/05	Cardiol Therapeutics Inc. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

CARDIOL THERAPEUTICS INC. : Canaccord Genuity toujours positif	24/05
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure	14/05
Cardiol Therapeutics Inc. Presents Phase II Archer Trial at the World Congress on Acute Heart Failure 2024	14/05
CARDIOL THERAPEUTICS INC. : HC Wainwright toujours positif	23/04
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Cardiol Therapeutics Inc. Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx? for Recurrent Pericarditis	21/02
Cardiol Therapeutics Receives Orphan Drug Designation From FDA for Lead Drug Candidate to Treat Pericarditis	15/02
Cardiol Therapeutics Enrolls Over 50% of Patients for Phase II ARCHER Trial in Acute Myocarditis	09/01
Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis	09/01
Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot	06/12
Cardiol Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Cardiol Therapeutics Inc. Announces 50% Enrollment in Its Phase Ii Maveric-Pilot Study in Recurrent Pericarditis	01/11
Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction	10/10/23
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx? for the Treatment of Acute Myocarditis	19/09/23
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
CARDIOL THERAPEUTICS INC. : Canaccord Genuity à l'achat	19/05/23
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23
Cardiol Therapeutics Says Studies Show Cannabidiol-Based CardiolRx 'Significantly' Prevents Heart Dysfunction	07/03/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cardiol Therapeutics Inc.

Acciones

CRDL

CA14161Y2006

Otros idiomas

Filtros